CAPR
Price
$7.97
Change
+$0.19 (+2.44%)
Updated
Aug 15, 04:59 PM (EDT)
Capitalization
363.91M
88 days until earnings call
QURE
Price
$16.18
Change
+$0.40 (+2.53%)
Updated
Aug 15, 04:59 PM (EDT)
Capitalization
887.75M
74 days until earnings call
Interact to see
Advertisement

CAPR vs QURE

Header iconCAPR vs QURE Comparison
Open Charts CAPR vs QUREBanner chart's image
Capricor Therapeutics
Price$7.97
Change+$0.19 (+2.44%)
Volume$18.31K
Capitalization363.91M
uniQure
Price$16.18
Change+$0.40 (+2.53%)
Volume$54K
Capitalization887.75M
CAPR vs QURE Comparison Chart in %
Loading...
CAPR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
QURE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CAPR vs. QURE commentary
Aug 16, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CAPR is a Hold and QURE is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 16, 2025
Stock price -- (CAPR: $7.96 vs. QURE: $16.18)
Brand notoriety: CAPR and QURE are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CAPR: 44% vs. QURE: 111%
Market capitalization -- CAPR: $363.91M vs. QURE: $887.75M
CAPR [@Biotechnology] is valued at $363.91M. QURE’s [@Biotechnology] market capitalization is $887.75M. The market cap for tickers in the [@Biotechnology] industry ranges from $100.71B to $0. The average market capitalization across the [@Biotechnology] industry is $1.86B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CAPR’s FA Score shows that 0 FA rating(s) are green whileQURE’s FA Score has 0 green FA rating(s).

  • CAPR’s FA Score: 0 green, 5 red.
  • QURE’s FA Score: 0 green, 5 red.
According to our system of comparison, both CAPR and QURE are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CAPR’s TA Score shows that 3 TA indicator(s) are bullish while QURE’s TA Score has 5 bullish TA indicator(s).

  • CAPR’s TA Score: 3 bullish, 5 bearish.
  • QURE’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, QURE is a better buy in the short-term than CAPR.

Price Growth

CAPR (@Biotechnology) experienced а -12.24% price change this week, while QURE (@Biotechnology) price change was +21.84% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +9.90%. For the same industry, the average monthly price growth was +26.70%, and the average quarterly price growth was +20.91%.

Reported Earning Dates

CAPR is expected to report earnings on Nov 12, 2025.

QURE is expected to report earnings on Oct 29, 2025.

Industries' Descriptions

@Biotechnology (+9.90% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
QURE($888M) has a higher market cap than CAPR($364M). QURE YTD gains are higher at: -8.381 vs. CAPR (-42.319). CAPR has higher annual earnings (EBITDA): -55.78M vs. QURE (-119.56M). QURE has more cash in the bank: 377M vs. CAPR (145M). CAPR has less debt than QURE: CAPR (1.25M) vs QURE (66.7M). CAPR has higher revenues than QURE: CAPR (17.4M) vs QURE (14.3M).
CAPRQURECAPR / QURE
Capitalization364M888M41%
EBITDA-55.78M-119.56M47%
Gain YTD-42.319-8.381505%
P/E RatioN/AN/A-
Revenue17.4M14.3M122%
Total Cash145M377M38%
Total Debt1.25M66.7M2%
FUNDAMENTALS RATINGS
CAPR vs QURE: Fundamental Ratings
CAPR
QURE
OUTLOOK RATING
1..100
1063
VALUATION
overvalued / fair valued / undervalued
1..100
73
Overvalued
79
Overvalued
PROFIT vs RISK RATING
1..100
90100
SMR RATING
1..100
98100
PRICE GROWTH RATING
1..100
4943
P/E GROWTH RATING
1..100
10092
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CAPR's Valuation (73) in the Biotechnology industry is in the same range as QURE (79). This means that CAPR’s stock grew similarly to QURE’s over the last 12 months.

CAPR's Profit vs Risk Rating (90) in the Biotechnology industry is in the same range as QURE (100). This means that CAPR’s stock grew similarly to QURE’s over the last 12 months.

CAPR's SMR Rating (98) in the Biotechnology industry is in the same range as QURE (100). This means that CAPR’s stock grew similarly to QURE’s over the last 12 months.

QURE's Price Growth Rating (43) in the Biotechnology industry is in the same range as CAPR (49). This means that QURE’s stock grew similarly to CAPR’s over the last 12 months.

QURE's P/E Growth Rating (92) in the Biotechnology industry is in the same range as CAPR (100). This means that QURE’s stock grew similarly to CAPR’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CAPRQURE
RSI
ODDS (%)
Bullish Trend 2 days ago
85%
N/A
Stochastic
ODDS (%)
Bearish Trend 2 days ago
85%
Bearish Trend 2 days ago
90%
Momentum
ODDS (%)
Bearish Trend 2 days ago
88%
Bullish Trend 2 days ago
79%
MACD
ODDS (%)
Bullish Trend 2 days ago
90%
Bullish Trend 2 days ago
77%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
85%
Bullish Trend 2 days ago
75%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
82%
Bullish Trend 2 days ago
74%
Advances
ODDS (%)
Bullish Trend 3 days ago
85%
Bullish Trend 2 days ago
76%
Declines
ODDS (%)
Bearish Trend 11 days ago
85%
Bearish Trend 8 days ago
86%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
82%
Bearish Trend 2 days ago
89%
Aroon
ODDS (%)
N/A
Bullish Trend 2 days ago
77%
View a ticker or compare two or three
Interact to see
Advertisement
CAPR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
QURE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
LMGTX62.97N/A
N/A
ClearBridge International Growth C
WMICX8.05N/A
N/A
Wasatch Micro Cap
PSGQX33.55N/A
N/A
PGIM Jennison Focused Growth R6
TRDIX8.45N/A
N/A
Transamerica Sustainable Equity Inc I2
EFCCX20.63N/A
N/A
Emerald Insights C

CAPR and

Correlation & Price change

A.I.dvisor tells us that CAPR and QURE have been poorly correlated (+31% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that CAPR and QURE's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CAPR
1D Price
Change %
CAPR100%
+2.31%
QURE - CAPR
31%
Poorly correlated
+2.53%
MDGL - CAPR
30%
Poorly correlated
-0.41%
CORT - CAPR
30%
Poorly correlated
-0.35%
XNCR - CAPR
30%
Poorly correlated
+0.39%
BEAM - CAPR
30%
Poorly correlated
+1.08%
More

QURE and

Correlation & Price change

A.I.dvisor indicates that over the last year, QURE has been loosely correlated with NAMS. These tickers have moved in lockstep 56% of the time. This A.I.-generated data suggests there is some statistical probability that if QURE jumps, then NAMS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To QURE
1D Price
Change %
QURE100%
+2.53%
NAMS - QURE
56%
Loosely correlated
-0.40%
BEAM - QURE
47%
Loosely correlated
+1.08%
ABSI - QURE
43%
Loosely correlated
-2.33%
AXON - QURE
42%
Loosely correlated
+0.59%
NRIX - QURE
42%
Loosely correlated
+0.19%
More